Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years old
- Diagnosed with rectal adenocarcinoma that is MSS/pMMR (a specific type of cancer) and located within 10 cm of the anus
- Tumor stage is T3-4/N+ (locally advanced) and has not spread to other parts of the body
- You are in reasonably good health (Karnofsky score of 70 or higher) and have not had prior cancer treatment or immunotherapy
- No other cancer in the past 5 years, no serious heart, kidney, or liver problems, and no active autoimmune disease or infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This study compares two different ways of delivering radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see which approach is more effective and safer for people whose cancer has not spread.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.